Haemato-oncology

This page shows the latest Haemato-oncology news and features for those working in and with pharma, biotech and healthcare.

European biosimilars hit AbbVie’s Humira revenues in Q4

The company has several years to build up its other franchises, which includes its haemato-oncology therapies.

EU approval for Opdivo combo in renal cell cancer

which underscores the need for new treatments for this disease,” said Bernard Escudier, MD, ex-chairman of the genitourinary oncology committee, Institut Gustave Roussy. ... NSCLC). BMS recently announced a $74bn acquisition of Celgene, a move which
Dragonfly signs Celgene as partner for NK cell platform

Extends presence in haemato-oncology and solid tumours. Immuno-oncology start-up Dragonfly Therapeutics has bagged a $24 million licensing deal from Celgene for two cancer therapeutics based on natural killer ... That differentiates TriNKETs from other
Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

BiTE will rival therapies from Bluebird, Celgene/Juno, J&J/Legend biotech
Regeneron’s early stage bispecific shows promise

Bispecifics and antibody drug conjugates will challenge CAR-Ts. The potentially revolutionary nature of CAR-Ts has made them the hottest properties in haemato-oncology in recent years, but a wave ... refractory follicular lymphoma patients," said Israel
Astellas, Catalyst approvals set up record year for FDA approvals

Xospata offers new hope to patients for whom the treatment path forward is unclear,” said Steven Benner, senior vice president and global therapeutic area head, Oncology Development, Astellas. “For the first ... The FDA green light is also big news

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Deal Watch table for July 2013

485. Array BioPharma / Loxo Oncology. Multi-year licence and collaboration. Drug candidate (preclinical) discovery of small molecule drugs for oncology targets. ... 208. Talon Therapeutics / Spectrum Pharmaceuticals. Acquisition. Haemato-oncology
Pharma deals during July 2013

neurology and haemato-oncology, respectively.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Scientific Director, MRNA/ Covid 19, Medical Communications, UK: Six figure salary

Medical Writers > Scientific Directors – Medical Communicatio...: Highly Competitive Salary, Bonus &Benefits

Client Services Director, MRNA/ Covid 19, Medical Communications...: Highly competitive salary

Account Supervisor – Leading Healthcare Advertising Agency – New...: Highly Competitive Salary, Bonus &Benefits

Principal Medical Writer, MRNA/ Covid 19, Medical Communications...: Highly competitive salary

HR Manager – Recruitment/ Generalist combined role, Marketing ag...: circa £50K

PR/ PA Account Executive (UK Healthcare Industry specialist, cam...: Competitive

Senior Account Exec > CSD – Medical Communications – UK, Lond...: Highly Competitive Salary, Bonus &Benefits

Vaccines writer – career opportunity to move into medcomms from ...: Highly competitive salary

Senior Medical Writer – Creative Healthcare Advertising – New Yo...: Highly Competitive Salary, Bonus &Benefits

Add my company

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Diversity in clinical trials: looking back at our 2021 blogs: In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?: Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:: Securing a future for telehealth with immersive market research insights...

Email:
Password: